STAT

Opinion: Covid-19 testing: overcoming challenges in the next phase of the epidemic

Which is a better proxy for estimating the #Covid19 infection rate in the United States: the infection rate in the NBA or the infection rate in China or Italy?
People line up to get tested for Covid-19 at Elmhurst Hospital in Queens, N.Y.

Which is a better proxy for estimating the Covid-19 infection rate in the United States: the infection rate in the NBA or the infection rate in China or Italy? The answer to that question reveals some of the pitfalls of diagnostic Covid-19 testing.

Kevin Durant, Rudy Gobert, and at least eight other NBA players have tested positive for Covid-19. The Jazz, Pistons, Nets, Lakers, and Celtics have all reported at least one positive test result for an active player, with 10 detected cases among the roughly 75 standard contract players on these teams. If this is representative of the rest of the NBA, then 13% of players are positive. Even if every other NBA team tested all its players and found no other positive results (a strong and doubtful assumption), the prevalence of Covid-19 in the league would be about 2%. And that is the low end of the possible range.

If 2% sounds low to you, here’s a reference point: Worldwide, at the time we write this,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks